Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
Public ClinicalTrials.gov record NCT01461915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer
Study identification
- NCT ID
- NCT01461915
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Dociparstat Drug
- Gemcitabine Drug
- Nab paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Nov 30, 2012
- Completion
- May 31, 2015
- Last update posted
- Jun 5, 2022
2011 – 2015
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Disney Family Cancer Center | Burbank | California | 91505 | — |
| Marin Cancer Care | Greenbrae | California | 94904 | — |
| Scripps Clinic Torrey Pines ( Green Hospital) | La Jolla | California | 92037 | — |
| Cleveland Clinic Florida | Weston | Florida | 33331 | — |
| Loyola University Medical Center/Cardinal Bernardin Cancer Center | Maywood | Illinois | 60153 | — |
| Indiana University Health, Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Fesit-Weiller Cancer Center | Shreveport | Louisiana | 71130 | — |
| Saint Mary's Health Care | Grand Rapids | Michigan | 49503 | — |
| Summa Health System - Cooper Cancer Center | Akron | Ohio | 44304 | — |
| Thomas Jefferson University [Kimmel Cancer Center] | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555 | — |
| South Texas Oncology & Hematology | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01461915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2022 · Synced Apr 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01461915 live on ClinicalTrials.gov.